Apolipoprotein Inhibitor

Opemalirsen is an antisense oligonucleotide targeted to apolipoprotein L1 (APOL1). It is used for the study of Kidney disorders.

Lepodisiran (LY3819469) sodium is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran sodium targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran sodium can be used in studies related to atherosclerotic cardiovascular disease.

Opemalirsen sodium scrambled negative control is the sequence scrambled negative control of Opemalirsen sodium.

MEDI-5884 (REG-101) is a humanized IgG4Pκ neutralizing monoclonal antibody targeting endothelial lipase (EL), with an IC₅₀ of 1.3 nM and 1.7 nM against human and cynomolgus monkey EL, respectively; its K_d values for human and cynomolgus monkey EL are 4.1 nM and 1.6 nM, respectively. MEDI-5884 increases plasma levels of HDL-C, apolipoprotein A1 (ApoA1) and phospholipids, while causing a slight increase in LDL-C and apolipoprotein B (ApoB) levels. MEDI-5884 can be used in research related to cardiovascular diseases, coronary heart disease, coronary atherosclerosis and stable coronary artery disease.

Lp(a)-IN-5 (Compound A) hydrochloride is an orally active lipoprotein (a) (Lp(a)) inhibitor. Lp(a)-IN-5 hydrochloride inhibits the assembly of Apo(a) and ApoB proteins with an IC₅₀ value of 0.41 nM. Lp(a)-IN-5 hydrochloride is promising for research of diseases related to elevated plasma Lp(a) levels, such as cardiovascular diseases.

Plozasiran sodium scrambled negative control is the sequence scrambled negative control of Plozasiran sodium.

Obicetrapib (TA-8995; DEZ-001) sodium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib sodium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib sodium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).

Lp(a)-IN-7 (example 1) is a lipoprotein (a) (Lp(a)) formation inhibitor with an IC₅₀ of 2.51 nM in conditioned media containing apolipoprotein B (apoB) and apolipoprotein(a). Lp(a)-IN-7 can be used for the study of cardiovascular disease.

Olezarsen sodium scrambled negative control is the sequence scrambled negative control of Olezarsen sodium.

Cy3 labled Zerlasiran sodium is a Cy3 labled Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.

apoB (4372-4392) is a potent lipoprotein(a) assembly inhibitor, with an IC₅₀ of 40 μM. apoB (4372-4392) can noncovalently bind to apolipoprotein(a) with high affinity.

Lp(a)-IN-5 (Compound A) is an orally active lipoprotein (a) (Lp(a)) inhibitor. Lp(a)-IN-5 inhibits the assembly of Apo(a) and ApoB proteins with an IC₅₀ value of 0.41 nM. Lp(a)-IN-5 is promising for research of diseases related to elevated plasma Lp(a) levels, such as cardiovascular diseases.

Tisbesiran is an apolipoprotein(a) (apo(a)) synthesis inhibitor. Tisbesiran is a trivalent GalNAc-conjugated double-stranded siRNA with a mixed modification of 2′-OMe/2′-F/P-thio. Its antisense strand targets the KIV-2 repeat region of human apo(a) (LPA) mRNA, thereby inhibiting apolipoprotein(a) synthesis and reducing plasma Lp(a). Tisbesiran can be used for research on Lp(a)-mediated atherosclerotic cardiovascular disease.